News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GENFIT Corp. (ALGFT) to Participate at the 5th Annual European Life Sciences CEO Forum in Zurich on March 6th - 7th, 2012



2/29/2012 11:25:39 AM

Lille (France), Cambridge (Massachusetts, United States), February 29th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation at the 5th Annual European Life Sciences CEO Forum, in Zurich on March 6th-7th, 2012.

During this conference, dedicated to partnering and investing in the Life Science and Biotech industries, Jean- François Mouney, CEO of GENFIT, will outline the Company’s perspectives to the pharmaceutical and specialized financial communities, and will notably present the latest results of toxicology studies and clinical trials obtained for GFT505 in NASH.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, …), to address these major public health concerns and their unmet medical needs.

GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT’s lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian

Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES